May 06, 2026

Distress Screening in a Cancer Survivorship Clinic: Impact on Psychosocial Referrals

This quality improvement project found that using a distress screening tool for head and neck cancer patients who were 2 or more years post-treatment led to an increased number of referrals for psychosocial needs.

Jadpro

April 08, 2026

Advancing early detection during Head and Neck Cancer Awareness Month

April is Head and Neck Cancer Awareness Month, highlighting a diverse group of diseases that account for nearly 5% of all cancers in the United States.

UCI Health

April 06, 2026

Oral and Head and Neck Cancers Rising: What You Need to Know

Most people know that tobacco use is a major risk factor for oral and head and neck cancers. Some even understand that excessive alcohol consumption also ups the odds.

Baptist Health South Florida

March 27, 2026

Pembrolizumab With or Without Lenvatinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

As reported in the Journal of Clinical Oncology by Licitra et al, the phase III LEAP-010 trial showed an improved objective response rate and progression-free survival—but not overall survival—with th...

The ASCO Post

February 24, 2026

Ultra–Low-Dose Immunotherapy in Relapsed or Refractory Solid Tumors

In an Indian single-center phase III trial (DELII) reported in the Journal of Clinical Oncology, Noronha et al found that “ultra–low-dose” immune checkpoint inhibitor therapy with nivolumab was associ...

The ASCO Post

February 02, 2026

Head and Neck Cancer: How Does Genetic Ancestry Impact Tumor Genomics?

Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African American patients survive for half as long as their counterparts of European ance...

The ASCO Post

January 28, 2026

Neoadjuvant Nivolumab Plus Chemotherapy and Response-Stratified CRT in HPV-Negative Head and Neck Cancer

In a single-center phase II trial (DEPEND) reported in JAMA Oncology, Rosenberg et al found that the combination of neoadjuvant nivolumab and chemotherapy followed by response-stratified chemoradiatio...

The ASCO Post

January 28, 2026

Concurrent vs Sequential Pembrolizumab With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Zandberg et al compared sequential vs concurrent pembrolizumab with chemoradiotherapy in patients with locally advanced head and neck ...

The ASCO Post

January 28, 2026

Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer

Combining the PD-1 inhibitor nivolumab and chemotherapy, and following that regimen with response-adapted chemoradiation, may an effective treatment for advanced human papillomavirus (HPV)-negative he...

The ASCO Post

January 28, 2026

Neoadjuvant Combination Immunotherapy for Head and Neck Cancer

A combination of two immunotherapies may improve treatment response among patients with head and neck squamous cell carcinomas compared with just one immunotherapy drug.

The ASCO Post